跳到正文
原文
STAT 主站· Adam Feuerstein·· 15 天前AI 评分38

ProMis Neurosciences 对抗阿尔茨海默病药物受挫

STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug

AI 导读

ProMis Neurosciences 针对阿尔茨海默病的药物在中期临床试验中未能减缓患者认知或功能衰退,股价因此大幅下跌。公司CEO表示此结果不应影响其药物的前景。

正文

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.

Shares of ProMis Neurosciences, developer of an amyloid-targeting treatment for Alzheimer’s disease, sold off sharply last week in reaction to an announcement from Acumen Pharmaceuticals that its own Alzheimer’s drug, with a similar mechanism, failed to slow the cognitive or functional decline of patients with Alzheimer’s disease compared to a placebo in a mid-stage study.

“This was a complete overreaction in my opinion and not justified,” ProMis CEO Neil Warma told me, when I asked if investors were correct to assume the failure of Acumen’s drug presaged a similar fate for ProMis’ drug.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com